
![]()
Key Takeaways
Peptides are emerging as a hot topic in fitness. They’re marketed as
the next big thing for fat loss, muscle recovery and “anti-aging,” often
promising faster results with less effort. Read on to learn the truth about
peptide-based drugs:
Peptides are emerging as a hot topic in fitness. They’re
marketed as the next big thing for fat loss, muscle recovery and “anti-aging,”
often promising faster results with less effort.
But here’s the uncomfortable truth: many injectable
peptide products being promoted in the fitness world are not approved by the
U.S. Food and Drug Administration (FDA), are not supported by strong scientific
evidence and, in some cases, may pose serious health risks.
What is a Peptide?
A peptide is a short chain of amino acids, which are the
building blocks of protein. Your body naturally produces thousands of peptides,
including hormones such as insulin and glucagon-like peptide-1 (GLP-1). Some
peptides act like hormones, sending signals that control hunger, growth, sleep
or other functions.
Because peptides can influence physiological systems, some
have been developed for use as medications. This is where confusion often
arises.
Certain peptide-based drugs—such as GLP-1 receptor
agonists—are prescribed by physicians and are FDA-approved medications
supported by large clinical trials and extensive safety monitoring. Others sold
online or through some “wellness clinics” are not FDA-approved, may be marketed
as “research chemicals” and often carry labels stating they are not intended
for human use. That distinction is critically important.
Peptide-based Medications That Are FDA-Approved
Two well-known examples of peptide-based medications are semaglutide (Wegovy) and tirzepatide (Zepbound), which are
approved for chronic weight management in specific patient populations.
Large randomized controlled trials published in the New
England Journal of Medicine showed impressive results:
These medications underwent years of research, dose-finding
studies and regulatory review, and their safety continues to be monitored after
approval.
Importantly, however, these results do not generalize to
other peptides that have not undergone similar testing.
Peptides Being Pushed by Fitness Influencers
In fitness circles, you may hear about BPC-157 and TB-500,
often promoted for muscle recovery, injury healing or tissue regeneration.
BPC-157 is part of a popular trend called the “Wolverine stack,” referencing
fictional rapid-healing abilities.
The scientific reality is much more limited:
Safety Concerns
Another major issue is product quality and regulation.
Products sold as research peptides are typically not subject to FDA
manufacturing oversight. As a result:
Apart from lack of oversight, risks related to
self-injection, such as infection, tissue injury and dosing errors, are
also concerns.
Concerns about quality should not be dismissed.
Investigations into peptides sold online have identified falsified or
substandard products, including products marketed as semaglutide
that contained different active ingredients. The FDA has also issued warnings
about dosing errors and adverse events associated with improperly prepared or
compounded GLP-1 medications.
If quality problems can occur with high-demand prescription
medications, the risk may be even greater with unregulated research peptides.
The Long-term Unknowns
One of the largest red flags is what we simply don’t know.
For many of these compounds, there are no long-term human safety trials
evaluating:
Using substances without this information
essentially means people are participating in uncontrolled personal
experiments—without appropriate monitoring, safety oversight or systematic data
collection.
What Happens When You Stop?
Even with FDA-approved medications like semaglutide and tirzepatide,
research shows that many people regain weight after stopping
treatment. Importantly, this indicates that these
drugs don’t “fix” metabolism permanently. If outcomes
change after stopping well-studied medications, the effects of
unapproved peptides—both benefits and risks—are even more unpredictable.
Why This Matters
Social media influencers often show dramatic
transformations and claim that peptides
are a “biohacking” effort or “next-level
optimization.” But when the goal
is health, performance or body composition improvement, the
strongest scientific support still points to
sustainable behaviors—like those outlined in the ACE 7 Core Drivers of Healthy LivingTM.
It’s also important to acknowledge why people consider
these options. Interest in experimental therapies often comes from
frustration, not vanity. Chronic pain, slow recovery,
persistent fatigue or unresolved health concerns can push people to
look for solutions outside of traditional care.
Those challenges are real—and they deserve thoughtful
medical evaluation, not shortcuts with uncertain risks and value.
Sometimes progress comes from:
The Bottom Line
If a substance is not FDA-approved, not backed by strong
human clinical trials, sold online as “research use only” and injected without
medical supervision, the risks are real and the benefits are uncertain.
Science advances carefully for a reason. Primarily, to
protect people. Certain aspects of the fitness and wellness industries move
fast because novelty and hype attract attention and sales. Before you inject
anything, ask:
|
If you are not sure
if a drug is FDA approved or safe for you it is best to consult
your doctor and check the FDA database for drug approval. |
If currently unapproved peptides are eventually shown to be
safe and effective through rigorous research, their use may become appropriate.
But until then, skepticism about gray market peptides isn’t negative. Rather,
it’s being a responsible health and exercise professional who follows the
evidence.
References
Aronne, L.J. et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults
with obesity: The SURMOUNT-4 randomized clinical trial. Journal of the
American Medical Association, 331, 1, 38–48.
Jastreboff, A.M.
et al. (2022). Tirzepatide once weekly for the
treatment of obesity. New England Journal of Medicine, 387, 3,
205–216.
Rubino, D. et al. (2021). Effect of continued weekly
subcutaneous semaglutide vs placebo on weight loss
maintenance in adults with overweight or obesity: The STEP 4 randomized
clinical trial. Journal of the American Medical Association, 325,
14, 1414–1425.
Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New
England Journal of Medicine, 384, 11, 989–1002.
Author
American Council on Exercise
Contributor